A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/2000 mg(25/1000 mg x 2 Tablets) in Comparison to Each Component Gemigliptin 50 mg and Metformin HCl Extended Release 2000 mg(1000 mg x 2 Tablets) Administered in Healthy Male Volunteers
Latest Information Update: 04 Jan 2018
Price :
$35 *
At a glance
- Drugs Gemigliptin/metformin (Primary) ; Gemigliptin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 15 Feb 2016 New trial record